Honasa Consumer's called-off ₹135 crore Fluence Pharma acquisition resurfaces from August

Mamaearth parent Honasa Consumer had terminated its proposed purchase of a 58% stake in nutraceuticals firm Fluence Pharma after closing conditions were not met, per an August 25 disclosure resurfacing now. The company said it will continue to assess organic and inorganic opportunities in nutraceuticals.

— FiledTue, 25 Aug, 2026, 22:00 IST·First seen Tue, 25 Aug, 2026, 22:00 IST·Source Entrackr

What happened

Mamaearth parent Honasa Consumer terminated its planned Rs 135 crore acquisition of a 58% stake in nutraceuticals firm Fluence Pharma after closing conditions

Key facts

  • Proposed acquisition: 58% stake in Fluence Pharma
  • Original enterprise value: around Rs 135 crore
  • Remaining stake planned: 42% in two tranches
  • Planned acquisition horizon: five to seven years
  • Fluence Pharma FY26 revenue: around Rs 40 crore
  • Fluence Pharma EBITDA margin: over 20%
  • Over 70% of revenue from hair-focused products
  • Network: over 3,000 dermatologists in India

Why this matters

Honasa’s withdrawal after unmet closing conditions underscores execution risk in wellness M&A, but its continued interest signals it remains an active buyer for credible nutraceutical assets.

What to watch

  • Management commentary on the specific unmet closing conditions and whether they were regulatory, commercial, financing or diligence-related.
  • Any announcement of a new nutraceutical partnership, minority stake, acquisition target or brand launch.
  • Launches of supplements, gummies, hair-loss products or dermatologist-endorsed ingestibles from Mamaearth or The Derma Co.
  • Changes in Honasa's cash balance, acquisition reserve, buyback/dividend posture or capital-allocation guidance.
  • Competitive moves by beauty, consumer-health and pharma companies entering hair and skin nutraceuticals.
  • Regulatory scrutiny of supplement claims, ingredients, labeling and celebrity or dermatologist endorsements in India.
  • Screen alternative dermatologist-backed, hair-loss, skin-health and women's-wellness nutraceutical targets.
  • Consider minority investments, commercial partnerships or distribution agreements before committing to a controlling acquisition.
  • Test ingestible beauty and hair-wellness products through D2C channels under existing brands.
  • Strengthen regulatory, quality-control and medical-claims diligence for any future wellness transaction.
  • Reassure investors that the terminated deal does not alter capital-allocation discipline or near-term profitability priorities.

Also reported by